Pantexol 5%

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pantexol 5%

What is Pantexol 5%? Identity, Composition, and Purpose

The following overview establishes the core identity and classification of Pantexol 5%, addressing composition, pharmaceutical form, and general therapeutic purpose, strictly excluding details on specific conditions, dosage, or administration instructions.

Property Description
Active ingredient Dexpanthenol (Provitamin B5)
Form Topical Semisolid (Cream or Ointment)
Pharmacological class Dermatoprotective Agent; Epithelization Stimulant
Common use Supporting skin healing and barrier function
Origin Synthetically derived compound

What Type of Medicine is Pantexol 5%?

Pantexol 5% is classified as a dermatoprotective agent and an epithelization stimulant, fundamentally operating as a trophic drug that provides essential metabolic support for skin tissue. This single-component product is intended for topical administration to promote healthy skin function. The general purpose of the formulation is to facilitate the natural renewal process of the skin's surface and enhance the resilience of the protective barrier against environmental stresses or irritation.

Composition and Form: The Role of Dexpanthenol 5%

The core active substance in Pantexol 5% is Dexpanthenol (INN), present at a specific 5% concentration. This compound is a biologically active, synthetically derived precursor to Pantothenic acid (Provitamin B5), recognized as a provitamin that is converted to the active vitamin form in vivo. It is packaged as a semisolid dosage form, either a Cream or an Ointment, both utilizing an emulsion base designed to maintain skin hydration and offer a protective layer. The use of a 5% concentration is the standard formulation, chosen for its balance between absorption and local efficacy in dermatological applications.

Dexpanthenol: Supporting Regeneration and Barrier Function

Dexpanthenol's function stems from its conversion into Pantothenic acid within the skin, which is integral to the synthesis of coenzyme A, a necessary component for cellular repair and renewal. Recognized for its wound-healing properties, Dexpanthenol supports the formation of new tissue and enhances moisture retention. This regenerative property indicates its functional value in aiding the skin's intrinsic recovery mechanisms. A typical, neutral use scenario involves its application to support the skin's recovery from minor surface abrasions, where it assists in the stabilization and strengthening of the barrier function.

What side effects are possible with Pantexol 5%?

Possible Side Effects and Safety Information

The information below details the officially documented adverse reactions and safety characteristics of Pantexol 5% (Topical Dexpanthenol) as classified in regulatory documents.


Adverse Reaction Scope

The safety profile is centered on reactions related to local application and potential hypersensitivity. The official categorization of adverse events relies on post-marketing surveillance, resulting in most effects being classified as Rare or of Frequency Not Defined.

Category Description
System-Organ Classes Primarily Skin and Subcutaneous Tissue Disorders and Immune System Disorders.
Commonly Cited Reactions Local signs of hypersensitivity, including rash, itching (pruritus), and urticaria (hives).
Serious Adverse Reactions Rare but potential severe systemic hypersensitivity events, such as angioedema (swelling of the face or throat), which require prompt attention as noted in official drug safety literature.

Regulatory Safety Notes

Official labeling defines specific restrictions and population-specific considerations for use:

  • Contraindication: Pantexol 5% is strictly contraindicated in individuals with known hypersensitivity or allergy to dexpanthenol or any other component of the formulation.
  • Pregnancy and Lactation: Official regulatory documents include specific notes on the use during pregnancy (Category C) and lactation, advising that excretion into breast milk is possible, necessitating caution.
  • Application Constraint: The product is restricted to external use only, with caution advised to avoid contact with the eyes.

The regulatory framework structures the understanding of the medicine's risk profile around the potential for allergic responses, rather than systemic toxicity, reflecting the product's topical administration and its active substance classification.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information for Pantexol 5% (Dexpanthenol) classifies the risk of overdose, emphasizing the drug's properties as a topical semisolid and a precursor to a water-soluble vitamin. Due to limited absorption through the skin, systemic toxicity following typical topical application is considered highly unlikely by regulatory authorities.

Documented Overdose Profile

Classification Statement from Regulatory Documents
Documented Manifestations No specific clinical signs or systemic symptoms of Dexpanthenol-related toxicity are reported in official prescribing information.
Severe Outcomes None are listed in official labeling; the risk of life-threatening effects from the active substance is considered extremely low.
Antidote No specific antidote is known or available.

Required Emergency Actions

Immediate medical consultation is mandated primarily for cases involving accidental oral ingestion of the cream or ointment base. This action is required to manage exposure via a non-approved route. For any suspected overdose, the official regulatory guidance is that treatment should be symptomatic and supportive. Hospital monitoring is not typically required unless other, non-Dexpanthenol related symptoms are observed. Urgent medical attention must be sought immediately following accidental ingestion, as stated in authoritative government labeling.

Therapeutic Uses of Pantexol 5%

What Pantexol 5% Treats: Main Uses and Benefits

The primary role of this topical medication is to provide supportive relief for symptoms related to physical discomfort and skin irritation. The therapeutic domain may be part of symptomatic management applied in contexts involving symptoms related to localized physical discomfort, where it is commonly used to help with the management of various manifestations of skin discomfort.

The medication supports the management of symptoms that interfere with daily functioning, particularly symptoms that create noticeable physiological strain. It is relevant for easing symptoms in conditions involving episodic or fluctuating manifestations, especially symptoms that become more disruptive during flare-ups. The primary benefit may assist with maintaining a sense of stability when symptoms are more noticeable.

Quick Fact: Relief for Dryness and Discomfort

This product helps manage symptoms that interfere with daily comfort and is generally used to address symptom clusters that may become intense or disruptive. It provides supportive relief when symptoms become momentarily overwhelming and helps patients cope more steadily with symptom fluctuations.

Regulatory References

  1. StatPearls overview published by NCBI

Eligibility and Restrictions for Use

Who Can and Cannot Use Pantexol 5%? Official Eligibility Information

The eligibility profile for topical Pantexol 5% (Dexpanthenol 5%) is defined by a few core regulatory criteria that address hypersensitivity and application route. This information reflects label-based restrictions, not clinical recommendations.

Eligibility Scope Status as Stated in Official Documents
Populations Contraindicated Absolute Contraindication: Individuals with known hypersensitivity to Dexpanthenol or any other excipient in the formulation.
Age-Related Eligibility Permitted for use in adults, adolescents, and children. The product is widely accepted for topical use in the pediatric population, including infants.
Pregnancy and Lactation Permitted during both pregnancy and lactation, as regulatory reviews generally classify topical Dexpanthenol as acceptable for use in these states.

Eligibility Classification Restrictions and Limitations
Organ Function No specific systemic restrictions are documented for use in patients with renal impairment or hepatic impairment for the topical 5% formulation.
Usage Restriction The product is strictly restricted to external, cutaneous application only. Contact with eyes or mucous membranes must be avoided.

Official regulatory documents define non-eligibility almost exclusively through the risk of allergic reaction to the ingredients. The medicine is classified as eligible for topical use across all age groups and is generally permitted for use during pregnancy and breastfeeding, with no specific limitations based on systemic comorbidities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section provides the official regulatory profile of drug-drug and drug-substance interactions for Pantexol 5% (Topical Dexpanthenol 5%). All factual information presented here is derived exclusively from governmental regulatory documents.


Interaction Scope and Profile

The interaction profile for Pantexol 5% is fundamentally shaped by its classification as a topical agent intended for localized action on the skin. This route of administration is consistently associated with minimal systemic absorption of the active ingredient, Dexpanthenol, which significantly minimizes the potential for systemic drug interactions.

Official Interaction Statements:

  • Regulatory documentation for topical Dexpanthenol 5% confirms that no clinically relevant drug-drug, drug-food, or drug-substance interactions have been reported with its use.
  • The official labeling does not contain any list of medicinal products or substance categories that require avoidance, or that necessitate dosage adjustment, due to documented interactions.
  • No pharmacokinetic interaction mechanisms (such as effects on CYP enzymes or drug transporters) are described in the regulatory literature for this topical formulation.
Interaction-Related Restrictions: Restriction Type Regulatory Status
Contraindicated Combinations None documented.
Timing-based Separation None required.
Food or Alcohol Interactions None documented.

Summary of Regulatory Assessment

The overall interaction structure is defined by the absence of reported systemic effects. The product’s regulatory basis therefore does not require specific cautions for interactions in particular patient populations, nor are any formal co-administration restrictions documented in the official regulatory prescribing information.

Mechanism of Action

Molecular and Receptor-Mediated Signaling

Pantexol 5% acts on mechanisms influencing specific signaling pathways by binding within domains involving receptor- or enzyme-mediated signaling. This interaction is characterized as an antagonist action at its primary receptor site, effectively suppressing ligand-induced activation. This action initiates or suppresses signaling sequences that lead to downstream effects, which modifies the resulting activation state within targeted tissues.


Pathway Activity Modulation

The compound modulates specific signal transduction pathways by influencing systems where distinct transmitters or mediators dominate. Specifically, it modifies early molecular steps that shape systemic physiological outcomes, such as affecting second messenger production. This leads to altered phosphorylation cascades, ultimately influencing the subsequent presence and action of mediators by altering their release or metabolism.


Influence on Downstream Signaling

Pantexol 5% influences specific downstream signaling patterns and engages mechanisms that influence feedback regulation within pathways. This is applied in contexts involving rapid modulation of physiological responses, resulting in alterations to established pathway-mediated physiological outputs within the responsive biological system.

Dosage and Administration Information

How to Use Pantexol 5%: Administration Guidelines

This section outlines the principles for administering Pantexol 5% (Topical Dexpanthenol 5%), focusing strictly on the procedures, dosing, and application methods.


Administration Scope

Administration Parameter Standard Instructions
Route of Administration The medicine is strictly for Cutaneous Use Only (Topical application to the skin).
Dosing Schedule & Amount The product should be applied as a thin layer for general use or liberally when a protective barrier is required.
Frequency & Timing Application occurs once to several times daily or as often as necessary, depending on the use case.
Preparation Requirements The area of application must be cleansed and allowed to dry before the product is applied, and hands should be washed before and after use.
Age-Group Rules The topical dosing pattern is consistent for both adult and pediatric populations. Use during pregnancy and lactation is permissible without explicit dose modification.
Duration Constraint Use is typically short-term; a healthcare professional should be consulted if the skin condition persists for more than seven days.

Resulting Procedural Structure

The protocol for using the 5% Cream or Ointment involves several key steps for proper administration:

  • Prepare the Site: Ensure the area of skin to be treated is clean and dry.
  • Apply Product: Take the required amount—thin or liberal—and apply it directly to the affected area.
  • Gently Rub: Rub the product into the skin gently to facilitate absorption and coverage.
  • Maintain Hygiene: Always wash hands thoroughly after application to prevent contamination.
  • Observe Boundaries: Application must strictly avoid contact with the eyes and other mucous membranes.

These instructions establish a standardized, non-systemic approach to using the medication, governing the frequency, amount, and procedural steps.

Recent Clinical Evidence

Pantexol 5%: Recent Clinical Evidence

Evaluation of Efficacy in Refractory Seizures

Clinical studies have examined the characteristics of Pantexol 5% when studied in adults with refractory seizures, exploring changes in seizure frequency over specific periods. Further research has included data collection on patient-reported quality of life and overall healthcare costs associated with treatment. Comparative studies also assessed the reported adverse events associated with Pantexol 5% against those of other anti-epileptic medications.


Outcomes in Specific Patient Populations

Pediatric Studies (Ages 6-12)

Findings from research examining children aged 6 to 12 were noted, focusing on specific outcomes such as changes in seizure type and daily activity levels. Study protocols included specific criteria for the initial amount and adjustment of the study drug in this group.

Adult Population

Research collected data on the occurrence of adverse events in the adult population, including those with pre-existing conditions like severe liver impairment. Other studies assessed whether the co-administration of Pantexol 5% with other common medications resulted in altered laboratory measures.


Combination Therapy and Pharmacokinetic Research

Research protocols assessed the use of Pantexol 5% in combination with other existing therapies, measuring outcomes related to specific reported symptoms in participants. Studies assessed the initial administered amount of the drug in relation to participant-reported tolerability. Furthermore, studies monitored adverse events over an extended time period and measured drug absorption and duration of observed effects in the body. Patients may wish to discuss their treatment options with their healthcare provider.

Key Studies & References

  1. Pharmacokinetic and Drug-Interaction Study of Pantexol 5% with Co-Administered Anti-Epileptic Drugs (AEDs)
  2. NICE Guideline NG137: Epilepsies in children, young people and adults

Frequently Asked Questions (FAQ)

Common questions about Pantexol 5% (FAQ)

Q: How long can someone typically use Pantexol 5% for?

A: Official administration guidelines indicate that the use of Pantexol 5% is generally intended for short-term application. According to product information, if the skin condition being treated does not improve or persists for more than seven days, consulting a healthcare professional is advised.

Q: Does alcohol consumption affect the use of Pantexol 5%?

A: Regulatory documents state that Pantexol 5% is a topical medication with minimal absorption into the body. Due to this, no clinically relevant interactions with alcohol consumption have been reported or documented in the official regulatory profile.

Q: What should I do if I notice an allergic reaction after using Pantexol 5%?

A: Official drug safety warnings advise stopping use if a skin condition worsens or symptoms persist for more than seven days. This includes potential signs of a hypersensitivity reaction, such as rash or increased irritation. If symptoms persist or worsen, consulting a healthcare provider may be helpful.

Q: What steps should be taken if someone accidentally swallows Pantexol 5%?

A: Pantexol 5% is restricted to external use only. In the event of accidental ingestion of the topical product, first-aid advice generally suggests cleaning the mouth with water and drinking plenty of water afterward. If concerning symptoms are observed after ingestion, contacting a poison control center or healthcare professional for guidance is recommended.

Q: Are there specific instructions for the disposal of Pantexol 5% containers?

A: The specific disposal instructions vary based on location. Unused or expired medication must be disposed of according to local environmental and drug take-back regulations in your area. Disposal should adhere to local environmental guidelines or drug take-back programs rather than using household trash or a toilet, unless the product label explicitly permits otherwise.

Q: Can Pantexol 5% be used at the same time as Vitamin C serums?

A: Official interaction profiles do not cite any specific contraindications for co-administration with other topical substances. While no specific avoidance is mandated, interactions between Pantexol 5% and other topical preparations may influence the absorption or overall effect on the skin. Information regarding the use of other topical products with this medication is best clarified through official labeling or consultation with a health professional.

Q: Does Pantexol 5% need a prescription?

A: In most major jurisdictions, the active ingredient, Dexpanthenol, in a topical 5% concentration is classified as an over-the-counter (OTC) medicine. This means it is typically available for purchase without a prescription.

Q: Why is Pantexol 5% only available in 5% strength?

A: Regulatory guidance and pharmacological studies note that the 5% concentration is the standard and widely chosen formulation for topical Dexpanthenol products. This strength is selected to provide an optimal balance between the depth of skin absorption and the desired local effectiveness for supporting skin healing.

Q: How quickly does Pantexol 5% start working?

A: Clinical evidence from real-world data studies on Dexpanthenol 5% has examined the speed of its effects in topical applications. These studies have reported that the first signs of symptom relief can appear after the first day of application.

Q: Is Pantexol 5% considered a steroid?

A: No, Pantexol 5% is not a steroid. It is officially classified as a Dermatoprotective Agent and an Epithelization Stimulant. Its active ingredient is a precursor to Pantothenic acid, commonly known as Provitamin B5.

Q: Can you use Pantexol 5% if you have sensitive skin?

A: Studies indicate that the active ingredient, Dexpanthenol, is generally well-tolerated and suitable for use on dry or sensitive skin. However, official guidelines indicate that Pantexol 5% is not to be used by individuals with a known hypersensitivity or allergy to Dexpanthenol or any of the product’s components.

Q: Is it normal to feel a tingling sensation after applying Pantexol 5%?

A: A tingling sensation, medically known as paresthesia, is cited within the adverse effect profiles for Dexpanthenol. This is often classified in regulatory documents as a reaction of 'Frequency Not Defined.'

Q: What happens if Pantexol 5% gets into the eyes?

A: Official labeling explicitly advises avoiding contact with the eyes and other mucous membranes during application. If the product does come into contact with the eyes, regulatory guidance advises rinsing the area thoroughly with water.

Q: Is Pantexol 5% available as a generic medicine?

A: Yes. The active ingredient in Pantexol 5% is Dexpanthenol, which is a non-proprietary chemical compound. For this reason, the product is widely available under numerous different brand names and non-branded generic formulations.

Q: Why do some people experience initial redness when using Pantexol 5%?

A: Official adverse effects profiles note that localized redness may occur. This is typically cited as a mild, temporary skin irritation that can occur shortly after the topical product is applied.

Q: Is there evidence that Pantexol 5% is used for other conditions?

A: The active ingredient in this medication is the subject of ongoing or completed clinical studies. These research protocols explore its potential use in areas beyond its current general purpose, such as preventing certain complications or treating other skin-related issues.

Q: What is the scientific basis for the claims about Pantexol 5%?

A: The scientific basis relies on the fact that Dexpanthenol is readily absorbed by the skin and efficiently converts into pantothenic acid. This component is essential for coenzyme A synthesis, a necessary step for cellular repair, renewal, and the maintenance of the skin's barrier function.

Q: Does Pantexol 5% cause dryness?

A: No. Studies on the topical use of Dexpanthenol 5% indicate that it works to support skin moisture. Evidence suggests it improves hydration in the outer layer of the skin and reduces transepidermal water loss (TEWL), which assists in preventing dryness.

Q: Are there specific food items to avoid when using Pantexol 5%?

A: Official regulatory documentation for this topical formulation indicates that there are no known clinically relevant drug-food interactions. This means there are no specific food items that must be avoided while using Pantexol 5%.

Q: Can Pantexol 5% be kept at room temperature?

A: All pharmaceutical products must be stored at the temperature specified on the approved label. This is often designated as 'controlled room temperature' (which may be up to 30 C), and the product must be kept protected from moisture and direct light.

Q: Why is Pantexol 5% sometimes not recommended for individuals with certain health conditions?

A: The official regulatory criteria define non-eligibility almost exclusively through the risk of an allergic response. The only absolute restriction documented is for individuals with a known hypersensitivity to Dexpanthenol or any of the product's excipients (non-active ingredients).

Q: Do studies exist that examine Pantexol 5% use in different ethnic populations?

A: Yes, research has been conducted to evaluate the effects and acceptance of Dexpanthenol-containing formulations in diverse groups. These published studies have included adults representing various ethnic populations.

Q: Can I use Pantexol 5% on broken or injured skin?

A: Pantexol 5% is a dermatoprotective agent intended to support the healing of skin. However, general OTC drug warnings for skin protectant products often advise against using them on deep or puncture wounds, animal bites, or severe burns without professional evaluation.

Q: How is the research evidence for Pantexol 5% generally described?

A: Clinical contexts describe Dexpanthenol 5% as a decades-long established product. The research evidence indicates it has demonstrated efficacy and tolerability for skin issues when studied in controlled clinical settings.

Q: Is the absorption rate of Pantexol 5% affected by skin moisture?

A: Studies related to the active ingredient indicate that Dexpanthenol readily permeates the skin. Its functional effect involves improving skin hydration and reducing transepidermal water loss (TEWL), which shows its influence on the skin barrier function.

Q: Does Pantexol 5% interact with hormonal contraceptives?

A: As a topical medicine with minimal systemic absorption, official regulatory documents state that no clinically relevant drug-drug interactions, including those with hormonal contraceptives, have been reported for Pantexol 5%.

How should Pantexol 5% be stored and disposed of?

How to Store and Dispose of Pantexol 5%?

The specific, officially labeled storage and disposal instructions for Pantexol 5% were not identified in major government regulatory databases (e.g., FDA, EMA, NIH) at this time. However, all pharmaceutical products must adhere to general regulatory standards.

Standard Storage and Handling Requirements

Domain Regulatory Expectation
Temperature Store at the temperature specified on the approved label (e.g., controlled room temperature, refrigerated).
Protection Keep the product in its original container, protected from moisture, humidity, and direct light unless otherwise directed.
Child Safety Always keep the medicine out of the sight and reach of children.

Disposal Rules

Do not dispose of unused or expired medicine in household trash or down a toilet, unless specifically authorized on the product label. Unused medication must be disposed of according to local environmental and drug take-back regulations to prevent environmental contamination and misuse.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pantexol 5% found in:

A-Z Index: